WAYNE, Pa., July 30, 2014 /PRNewswire/ -- Ryan & Maniskas, LLP has commenced an investigation into potential securities law violations by certain officers of Galectin Therapeutics, Inc. ("Galectin" or the "Company") (NASDAQ: GALT).

Galectin shareholders who purchased Galectin shares should contact Richard A. Maniskas, Esquire at 877-316-3218 or at rmaniskas@rmclasslaw.com to learn more about this investigation or visit: www.rmclasslaw.com/cases/galt.

Galectin, a development stage company, is engaged in the research and development of therapies for fibrotic disease and cancer. The investigation relates to the publication of a July 28, 2014, article that disclosed that the Company had hired a stock promotions firm to tout its securities. The investigation also relates to the Company's July 29, 2014, disclosure that its experimental drug GR-MD-02, which was being developed for the treatment of fatty liver disease, showed little difference from a placebo in its Phase 1 study. On this news, shares of Galectin declined $8.84 per share, or 60.80%, to close on July 29, 2014, at $5.70 per share, on unusually heavy volume.

If you own Galectin shares and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free: (877) 316-3218 or visit: www.rmclasslaw.com/cases/galt. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

Logo - http://photos.prnewswire.com/prnh/20121112/MM11729LOGO

SOURCE Ryan & Maniskas, LLP